High-dose therapy with ropinirole in patients with Parkinson's disease

被引：0
|
作者：
M. Müngersdorf
U. Sommer
M. Sommer
H. Reichmann
机构：
[1] Department of Neurology,
[2] Technical University of Dresden,undefined
[3] Dresden,undefined
[4] and,undefined
[5] Department of Clinical Neurophysiology,undefined
[6] Center for Neurological Medicine,undefined
[7] University of Göttingen,undefined
[8] Göttingen,undefined
[9] Federal Republic of Germany,undefined
来源：
Journal of Neural Transmission | 2001年 / 108卷
关键词：
Keywords: Ropinirole; high-dose therapy; dyskinesias; motor fluctuations; dopamine agonist; Parkinson's disease.;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Ropinirole is effective as mono- and combination therapy in PD. Previous studies have used a maximal dose of 24 mg/day; the present study assesses the effect of higher doses (up to 36 mg/day) on patients with motor fluctuations. Outcome measures were changes in the motor function score of the Unified Parkinson's Disease Rating Scale, the duration of dyskinesias and reductions in levodopa dose.
引用
收藏
页码：1309 / 1317
页数：8
相关论文
共 50 条
  • [21] Ropinirole in patients with advanced Parkinson's disease: prospective study
    Relja, M.
    Telarovic, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 : 116 - 116
  • [22] Cabergoline versus ropinirole as add-on therapy in Parkinson's disease
    Unal, Z
    Boylu, E
    Orhan, S
    MOVEMENT DISORDERS, 2005, 20 : S96 - S96
  • [23] Ropinirole versus pramipexole as adjunctive therapy to levodopa in Parkinson's disease
    Barbato, L
    Cattaneo, C
    Monge, A
    Nordera, G
    MOVEMENT DISORDERS, 2002, 17 : S49 - S49
  • [24] Ropinirole versus pergolide as adjunctive therapy to levodopa in Parkinson's disease
    Unal, Z
    Boylu, E
    Orhan, S
    MOVEMENT DISORDERS, 2004, 19 : S278 - S278
  • [25] High-dose statin therapy in patients with coronary artery disease
    Trouton, T. G.
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2005, 35 (02): : 110 - 111
  • [26] Intravenous levodopa in hallucinating Parkinson's disease patients: High-dose challenge does not precipitate hallucinations
    Goetz, CG
    Pappert, EJ
    Blasucci, LM
    Stebbins, GT
    Ling, ZD
    Nora, MV
    Carvey, PM
    NEUROLOGY, 1998, 50 (02) : 515 - 517
  • [27] HIGH-DOSE THERAPY IN CHEMOREFRACTORY HODGKIN'S LYMPHOMA PATIENTS
    Karamanesht, E.
    Shestovska, Y.
    Korenkova, S.
    Dushko, L.
    Reztsova, K.
    Makovey, E.
    Kostyukova, N.
    Turchanovskiy, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 551 - 551
  • [28] New approaches to the treatment of Parkinson's disease: Current findings on neuroprotection and high-dose therapy with dopamine agonists
    不详
    PSYCHIATRISCHE PRAXIS, 1997, 24 (06) : 2 - +
  • [29] Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study
    Itti, Emmanuel
    Villafan, Gabriel
    Malek, Zoulikha
    Brugieres, Pierre
    Capacchione, Daniela
    Itti, Laurent
    Maison, Patrick
    Cesaro, Pierre
    Meignan, Michel
    NUCLEAR MEDICINE COMMUNICATIONS, 2009, 30 (07) : 513 - 518
  • [30] Prospective study on the use of ropinirole in patients with advanced Parkinson's disease
    Relja, M
    Telarovic, S
    MOVEMENT DISORDERS, 2004, 19 : S214 - S214
12345